Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2281 to 2295 of 8981 results

  1. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [review of TA658] [ID4067]

    In development Reference number: GID-TA10979 Expected publication date: TBC

  2. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development Reference number: GID-TA10832 Expected publication date: TBC

  3. Tocilizumab for treating systemic sclerosis [ID1396]

    Awaiting development Reference number: GID-TA10346 Expected publication date: TBC

  4. Mavorixafor for treating WHIM syndrome [ID3946]

    Awaiting development Reference number: GID-TA10833 Expected publication date: TBC

  5. Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915]

    Awaiting development Reference number: GID-TA10791 Expected publication date: TBC

  6. Paclitaxel + XR17 (Paclical) with carboplatin for ovarian cancer [TSID5462]

    Topic prioritisation

  7. NPJ5008 for treating malignant hyperthermia [TSID11829]

    Topic prioritisation

  8. TAK-880 for managing primary immunodeficiency diseases in people hypersensitive to IgA [TSID11883]

    Topic prioritisation

  9. IgPro20 for treating dermatomyositis [TSID12014]

    Topic prioritisation

  10. Cyanoacrylate glue for hernia mesh fixation

    Topic prioritisation

  11. Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

    Topic prioritisation

  12. Technologies for the rapid diagnosis of endometriosis: early use assessment

    In development Reference number: GID-HTE10082 Expected publication date:  08 October 2026

  13. Unilateral and staged bilateral MRI-guided focused ultrasound thalamotomy for medication-refractory essential tremor

    In development Reference number: GID-IPG10441 Expected publication date:  17 December 2026

  14. Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]

    In development Reference number: GID-TA11866 Expected publication date: TBC

  15. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6454]

    In development Reference number: GID-TA11592 Expected publication date: TBC